Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcino...
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
About this item
Full title
Author / Creator
Gore, M E , Szczylik, C , Porta, C , Bracarda, S , Bjarnason, G A , Oudard, S , Lee, S-H , Haanen, J , Castellano, D , Vrdoljak, E , Schöffski, P , Mainwaring, P , Hawkins, R E , Crinò, L , Kim, T M , Carteni, G , Eberhardt, W E E , Zhang, K , Fly, K , Matczak, E , Lechuga, M J , Hariharan, S and Bukowski, R
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background:
We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.
Methods:
Patients ⩾18 years received oral sunitinib 50 mg per day on a 4-weeks-on–2-weeks-off sched...
Alternative Titles
Full title
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4647545
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4647545
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/bjc.2015.196
